{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:56:21Z","timestamp":1763016981296},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1053\/j.seminoncol.2009.10.009","type":"journal-article","created":{"date-parts":[[2009,12,5]],"date-time":"2009-12-05T04:11:38Z","timestamp":1259986298000},"page":"S18-S25","source":"Crossref","is-referenced-by-count":41,"special_numbering":"S3","title":["Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing Considerations"],"prefix":"10.1053","volume":"36","author":[{"given":"Joseph P.","family":"Boni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Hug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathie","family":"Leister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryl","family":"Sonnichsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2009.10.009_bib1","series-title":"Torisel [package insert]","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib2","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib3","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(89)90417-0","article-title":"Rapamycin for immunosuppression in organ allografting","volume":"2","author":"Calne","year":"1989","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib7","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib8","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib9","first-page":"3749S","article-title":"Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779 [abstract 477]","volume":"7","author":"Skotnicki","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib10","doi-asserted-by":"crossref","first-page":"10320","DOI":"10.1073\/pnas.171060098","article-title":"An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten+\/\u2212 mice","volume":"98","author":"Podsypanina","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib11","first-page":"1758","article-title":"Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition","volume":"7","author":"Dudkin","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib12","first-page":"2887","article-title":"Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients","volume":"9","author":"Peralba","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib13","first-page":"5027","article-title":"Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779","volume":"62","author":"Shi","year":"2002","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib14","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1158\/0008-5472.CAN-07-6487","article-title":"A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis","volume":"68","author":"Shor","year":"2008","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/annonc\/mdg248","article-title":"Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors","volume":"14","author":"Punt","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib16","unstructured":"Boni J, Burns J, Hug B, Sonnichsen D. mTOR inhibition following a single intravenous infusion of temsirolimus in healthy individuals. Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; San Francisco, CA; October 22-27, 2007."},{"key":"10.1053\/j.seminoncol.2009.10.009_bib17","unstructured":"Leister C, Hug B, Burns J, Smith K, Mauer AM, Boni J. Correlation of temsirolimus (CCI-779) pharmacokinetic exposure to safety in healthy subjects and patients with cancer following once-weekly iv treatment. Presented at: American Society for Clinical Pharmacology and Therapeutics; Anaheim, CA; March 21-24, 2007."},{"key":"10.1053\/j.seminoncol.2009.10.009_bib18","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1634\/theoncologist.2008-0120","article-title":"Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies","volume":"13","author":"Hutson","year":"2008","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/B:DRUG.0000036685.72140.03","article-title":"Phase I\/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs","volume":"22","author":"Chang","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib20","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1177\/0091270007306957","article-title":"Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications","volume":"47","author":"Boni","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib21","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1124\/dmd.107.014746","article-title":"In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites","volume":"35","author":"Cai","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib22","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clpt.2004.08.025","article-title":"Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer","volume":"77","author":"Boni","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1020943029130","article-title":"A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine","volume":"27","author":"Snoeck","year":"1999","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1359-6349(06)70557-2","article-title":"Integrated population pharmacokinetic analysis of temsirolimus in cancer patients following weekly IV treatments [abstract 552]","volume":"4","author":"Boni","year":"2006","journal-title":"Eur J Cancer Suppl"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib26","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2008.19.3144","article-title":"Temsirolimus in patients with renal cancer on hemodialysis","volume":"26","author":"Lunardi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib27","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/sj.bjc.6604376","article-title":"Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus","volume":"98","author":"Boni","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00280-008-0865-9","article-title":"Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus","volume":"64","author":"Boni","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl 18S","key":"10.1053\/j.seminoncol.2009.10.009_bib29","first-page":"141s","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies [abstract 3512]","volume":"25","author":"Patnaik","year":"2007","journal-title":"J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I"},{"key":"10.1053\/j.seminoncol.2009.10.009_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3816\/CGC.2009.n.004","article-title":"Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma","volume":"7","author":"Patel","year":"2009","journal-title":"Clin Genitourin Cancer"},{"issue":"Suppl 18S","key":"10.1053\/j.seminoncol.2009.10.009_bib31","first-page":"243s","article-title":"Phase I\/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results [abstract 5034]","volume":"25","author":"Merchan","year":"2007","journal-title":"J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409001912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409001912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T15:53:47Z","timestamp":1544802827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775409001912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":31,"alternative-id":["S0093775409001912"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2009.10.009","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}